Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00071136 · ClinicalTrials.gov registry record · Phase 1
Pemetrexed and Gemcitabine in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
A Phase 1 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 48
- Enrollment target
NCT00071136 is a Phase 1 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 48 participants.
The verdict
NCT00071136, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 48 participants
- Enrollment target
Study Summary
This is a Phase 2 study of pemetrexed and gemcitabine chemotherapy given once every 14 days to patients with advanced stage non-small cell lung cancer. This treatment is for patients that have not received any prior chemotherapy treatment for lung cancer. The primary goal is to find out if the tumor gets smaller or disappears with this treatment.
Interventions
- DRUG pemetrexed
- DRUG gemcitabine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2003-12 |
| Est. Completion | 2006-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00071136
The ClinicalTrials.gov registry entry for NCT00071136 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which pemetrexed is the first listed.
NCT00071136 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00071136 about?
NCT00071136 is a clinical study titled "Pemetrexed and Gemcitabine in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)". This is a Phase 2 study of pemetrexed and gemcitabine chemotherapy given once every 14 days to patients with advanced stage non-small cell lung cancer. This treatment is for patients that have not received any prior chemotherapy treatment for lung cancer. The primary goal is to find out if the tumor...
What is the current status of trial NCT00071136?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 48 participants. The study started on 2003-12. Estimated completion is 2006-08.
What interventions are being tested in trial NCT00071136?
The interventions under investigation include: pemetrexed (DRUG), gemcitabine (DRUG).
Who is sponsoring clinical trial NCT00071136?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.